Transcutaneous Electrical Acupoint Stimulation for Perioperative Sleep Disturbances in Cancer Patients

Postoperative sleep disturbance (POSD) is highly prevalent among cancer patients after tumor resection, affecting 43%-80% of perioperative individuals. Poor sleep aggravates postoperative pain, anxiety and adverse cardiovascular events, hindering postoperative recovery. Conventional hypnotic medicines carry potential risks of drug dependence and respiratory depression. Transcutaneous Electrical Acupoint Stimulation (TEAS) is a non-invasive physical therapy derived from traditional acupuncture, which delivers low-frequency electrical stimulation on acupoints. Previous small-scale researches suggest TEAS may improve perioperative sleep, but high-quality randomized controlled trial evidence for cancer surgical patients is insufficient. This single-center randomized sham-controlled trial aims to verify whether perioperative TEAS at Shenmen (HT7), Neiguan (PC6) and Hegu (LI4) can improve postoperative sleep quality, relieve surgical pain and regulate stress hormone level. A total of 176 eligible patients aged 18-75 years undergoing elective gastrointestinal or gynecologic cancer resection under general anesthesia will be enrolled and randomly divided into 1:1 intervention group and sham control group. The TEAS group receives acupoint electrical stimulation from pre-anesthesia to the end of surgery, while control group uses identical electrodes without actual electrical output. All subjects receive standardized anesthesia and routine postoperative analgesia. Researchers evaluate primary outcomes including PSQI and AIS sleep scales, alongside secondary indicators such as VAS pain score, QoR-15 and serum cortisol at postoperative Day1, Day3, Day7 and postoperative 30-day follow-up.

Sex

All

Minimum age

18 Years

Maximum age

75 Years

Inclusion Criteria:

* Patients aged between 18 and 75 years old, regardless of gender.
* Diagnosed with malignant tumors requiring elective surgery under general anesthesia.
* ASA physical status I-III.
* Able to understand and complete study-related questionnaires (PSQI, AIS, NRS, etc.).
* Voluntarily sign the informed consent form.

Exclusion Criteria:

* Severe cardiac, hepatic, renal or respiratory dysfunction that affects the implementation of TEAS.
* History of psychiatric disorders or use of psychotropic drugs.
* History of drug or alcohol abuse.
* Presence of infection, skin lesions or contraindications at TEAS acupoints.
* Preoperative use of strong opioids (e.g., morphine, oxycodone) for more than 1 week.
* Pregnant or lactating women.
* Participation in other clinical trials within 3 months prior to enrollment.
* Inability to cooperate with the study due to cognitive impairment or language barriers.